Oragenics Inc
Research Oragenics Inc (OGEN) on Bullrun: market cap USD 2.28M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerOGEN
- ExchangeNYSE MKT
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 2.28M
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 9.83M
- Free cash flow-USD 9.33M
Valuation Snapshot
latest market cap is USD 2.28M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 984.25M | -USD 9.25M | n/a | -4.56 | USD 4.40M | USD 227.35K | USD 8.28M |
| FY2024 | USD 0 | -USD 1.06B | -USD 8.60M | n/a | -47.88 | USD 864.84K | USD 328.53K | -USD 211.89K |
| FY2023 | USD 37.65K | -USD 20.66M | n/a | n/a | -9.18 | USD 3.48M | USD 517.76K | USD 3.17M |
| FY2022 | USD 131.52K | -USD 14.29M | -USD 15.36M | n/a | -7.11 | USD 11.43M | USD 398.18K | USD 13.01M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 2.28M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 641.86K | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 4.65M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 17.35M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 12.91M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 52.41M | n/a | n/a | n/a |
About Oragenics Inc
Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical therapies neurological conditions and infectious diseases in the United States. Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid, which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification for the treatment of mild traumatic brain injury.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Oragenics Inc's market cap?
Oragenics Inc's market capitalization is USD 2.28M.
What does Oragenics Inc do?
Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical therapies neurological conditions and infectious diseases in the United States. Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid, which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification for the treatment of mild traumatic brain injury. The company was formerly known as Oragen, Inc. Oragenics, Inc.